The latest study showed that CD33-targeting CAR NK cells combined the broad expression advantage of CD33 targets and the safety of NK cells, effectively eliminating the engraftment of CD33+ AML cells in the BM and spleen [141]. Here, CD33 is linked to acute myeloid leukemia.